Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
Aaron C. Logan(University of California, San Francisco), Razan Mohty(University of Alabama at Birmingham), Joshua Sasine(Cedars-Sinai Medical Center), Catherine J. Lee(University of Utah), Fevzi Yalniz, Matthew L. Ulrickson, Paul Shaughnessy(CHRISTUS Transplant Institute), Navneet S. Majhail(Sarah Cannon), Aravind Ramakrishnan(Fred Hutch Cancer Center), Marlise R. Luskin(Dana-Farber Cancer Institute), Sumithira Vasu(The Ohio State University), Omer Jamy(University of Alabama at Birmingham Hospital), Jacob Boccucci(Augusta University Health), Luke Mountjoy(Colorado Blood Cancer Institute), Jessica Leonard(Oregon Health & Science University), Evandro D. Bezerra(Cleveland Clinic), Tamer Othman(City Of Hope National Medical Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ibrahim Aldoss(City of Hope), Michael R. Grunwald(Levine Cancer Institute), Noam E. Kopmar(University of Washington), Evan C. Chen(Dana-Farber Cancer Institute), LaQuisa C. Hill(Baylor College of Medicine), John Mathews, Ibrahim N. Muhsen, Vamsi Kota(Augusta University), Karamjeet Sandhu, Jae H. Park(University of Tennessee at Knoxville), Talal Hilal(WinnMed), Chenyu Lin(Duke University), Ryan D. Cassaday(University of Washington), Minoo Battiwalla(Sarah Cannon), Anjali S. Advani(Cleveland Clinic), Hrishikesh K. Srinagesh(Stanford University), Ran Reshef(Abramson Cancer Center), Kristen M. O'Dwyer(University of Rochester Medicine), Yannis K. Valtis(Brigham and Women's Hospital), Virginia Tan(Oregon Health & Science University), Timothy E. O’Connor(University of Northern Iowa), Ross McCauley(Roswell Park Comprehensive Cancer Center), Nikeshan Jeyakumar(Stanford Blood Center), Amy Zhang, Shahbaz A. Malik(University of Nebraska at Omaha), Katherine Sutherland, Katharine Miller(Stanford University), Jozal Moore(University of Rochester Medicine), Ali Al-Darobi(The University of Texas MD Anderson Cancer Center), Melhem Solh(Johns Hopkins Hospital)
Cited by 2
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655